Printer Friendly

Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off Aug 06, 2019.

ENPNewswire-August 7, 2019--Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off Aug 06, 2019

(C)2019 ENPublishing -

Release date- 06082019 - STAINES-UPON-THAMES - Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported results for the three months ended June 28, 2019.

Unless otherwise noted, the quarter comparisons are to the recast prior year comparable three months ended June 29, 2018.

Net sales were $823.3 million in the quarter with diluted loss per share from continuing operations of $0.01 compared with income per share of $0.04. Adjusted diluted EPS were $2.53 versus $2.16, an increase of 17.1%.

'We're pleased to have delivered a strong first half of the year, highlighted by the solid operational performance of all hospital products, AMITIZA, and the Specialty Generics segment, along with good progress on our Acthar Gel data generation efforts,' said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. 'We expect additional new Acthar Gel clinical data sets to continue to emerge this year, including more on rheumatoid arthritis, as well as topline results for the multiple sclerosis registry and lupus clinical trial. Phase 3 topline results for StrataGraft regenerative tissue and terlipressin development products are anticipated in the next three months as well.

'We are also happy with the strength of our operating cash flows and the continued execution of our capital allocation strategy, allowing us to reduce net debt to its lowest level since 2015. Given the strength of our hospital products and the success of our debt reduction efforts, we are pleased to once again raise guidance for adjusted diluted EPS,' Trudeau continued. 'We continue to execute on our transformation into an innovation-driven biopharmaceutical company.'


Mallinckrodt's long-standing goal remains to be an innovation-driven biopharmaceutical company focused on improving outcomes for underserved patients with severe and critical conditions. However, based on current market conditions and developments, including increasing uncertainties created by the opioid litigation, the company is suspending for now its previously announced plans to spin off the Specialty Generics company. Mallinckrodt continues to actively consider a range of options intended to lead to the ultimate separation of the Specialty Generics business, consistent with its previously stated strategy.


Gross profit was $388.9 million with gross profit as a percentage of net sales of 47.2%, compared with 47.7%. Adjusted gross profit was $603.9 million, compared with $608.1 million, with adjusted gross profit as a percentage of net sales of 73.4%, compared with 73.7%.

Selling, general and administrative (SG&A) expenses were $225.9 million or 27.4% of net sales, as compared to $189.9 million, or 23.0%, driven primarily by separation costs in the quarter and the prior year change in the fair value of contingent consideration. Adjusted SG&A expenses were $208.6 million or 25.3% of net sales, compared with $215.8 million or 26.1%. Adjusted SG&A expenses decreased due to focused efforts on SG&A reduction including benefits from restructuring and acquisition synergies, partially offset by increased legal expenses.

Research and development expenses were $79.6 million or 9.7% of net sales, as compared to $92.6 million or 11.2%, due primarily to the timing of certain developmental milestone payments in the prior year.

Interest expense was $71.5 million as compared to $95.1 million, a reduction of 24.8%, driven by Mallinckrodt's strong operating cash flows, allowing for debt reduction, and the $8.6 million reversal of deferred interest associated with the interest-bearing deferred tax obligations.

Income tax benefit was $24.3 million, for an effective tax rate of 98.0%. The adjusted effective tax rate was 17.6%.

Six-Month Fiscal 2019 Results

Net sales were $1,613.9 million, up 2.1% compared with $1,580.8 million. The increase is primarily attributed to strength in the hospital products and AMITIZA (lubiprostone), and partially offset by Acthar Gel (repository corticotropin injection).

On a GAAP1 basis, net income was $161.7 million, compared with a loss of $2.4 million. Diluted EPS were $1.92 compared with loss per share of $0.03.

Adjusted net income was $377.4 million, compared with $320.1 million. Adjusted diluted EPS were $4.48 compared with $3.77.


Specialty Brands Segment

Net sales for the segment in the second quarter 2019 were $627.8 million.

Acthar Gel net sales were $266.4 million, a 9.1% decrease, driven primarily by continued reimbursement challenges impacting new and returning patients, and continued payer scrutiny on overall specialty pharmaceutical spending.

INOMAX (nitric oxide) gas, for inhalation, net sales were $139.7 million, up 6.6% due to continued, consistent demand, and multi-year contract renewals.

OFIRMEV (acetaminophen) injection net sales were $90.5 million, an increase of 5.7%, benefiting from continued strong demand partially offset by typical quarter-to-quarter order variability.

Therakos immunology platform net sales were $60.9 million, an increase of 7.2%, or 9.1% on a constant-currency basis, primarily on growth in the U.S.

AMITZA net sales were $52.0 million, up 8.3% due to continued strong utilization in Japan, partially offset by a more competitive landscape in the U.S.

Specialty Generics Segment

The segment reported net sales in the second quarter 2019 of $195.5 million, an increase of 0.9%, or 1.0% on a constant currency basis, driven by continued share recapture in the base business.


Cash provided by operating activities in the quarter was $302.9 million, with free cash flow of $265.1 million. Through the first two quarters of 2019, operating cash flow has been $467.4 million and free cash flow $389.8 million. Significant progress has been made toward Mallinckrodt's debt reduction goals, with net debt at its lowest level since 2015 at $5.350 billion.

Subsequent to the quarter close, the company borrowed an additional $400.0 million on its revolving credit facility, with $95.0 million remaining capacity on this facility. Mallinckrodt has used these borrowings to voluntarily terminate its $200.0 millionreceivable securitization and has repurchased fixed-rate debt aggregating to a principle of $70.9 million, resulting in a gain on repurchase of $18.0 million. The current cash balance as of today exceeds $450 million.


Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


This press release contains financial measures, including adjusted net income, adjusted diluted earnings per share, adjusted gross profit, adjusted SG&A, net sales growth on a constant-currency basis, adjusted effective tax rate, net debt and free cash flow, which are considered 'non-GAAP' financial measures under applicable SEC rules and regulations.

Adjusted net income, adjusted gross profit and adjusted SG&A represent amounts prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and adjusted for certain items that management believes are not reflective of the operational performance of the business. The adjustments for these items are on a pre-tax basis for adjusted gross profit and adjusted SG&A and on an after-tax basis for adjusted net income. Adjustments to GAAP amounts include, as applicable to each measure, amortization; restructuring and related charges, net; inventory step-up expenses; discontinued operations; changes in fair value of contingent consideration obligations; acquisition-related expenses; losses/gains on repurchase of debt; separation costs; tax effects of aforementioned adjustments, changes in related uncertain tax positions, as well as impacts from certain transactions, such as acquisitions or reorganizations and other items identified by the company. Adjusted diluted earnings per share represent adjusted net income divided by the number of diluted shares.

The adjusted effective tax rate is calculated as the income tax effects on continuing and discontinued operations plus the income tax impact included in Mallinckrodt's reconciliation of net income, divided by income from continuing and discontinued operations plus the pre-tax, non-income, tax-related adjustments included in its reconciliation of adjusted net income (excluding dilutive share impact). The income tax adjustment included in the reconciliation of adjusted net income primarily represents the tax impact of adjustments between net income and adjusted net income, changes in related uncertain tax positions, as well as tax impacts from certain transactions, such as acquisitions or reorganizations.

Net sales growth on a constant-currency basis measures the change in net sales between current- and prior-year periods using a constant currency, the exchange rate in effect during the applicable prior-year period.

Free cash flow for the second quarter represents net cash provided by operating activities $302.9 million less capital expenditures of $37.8 million, each as prepared in accordance with GAAP.

Free cash flow for the year to date represents net cash provided by operating activities $467.4 million less capital expenditures of $77.6 million, each as prepared in accordance with GAAP.

Net debt as of June 28, 2019 represents total debt principal of $5,591.0 million less cash of $241.1 million, each as prepared in accordance with GAAP.

The company has provided these adjusted financial measures because they are used by management, along with financial measures in accordance with GAAP, to evaluate the company's operating performance. In addition, the company believes that they will be used by certain investors to measure Mallinckrodt's operating results. Management believes that presenting these adjusted measures provides useful information about the company's performance across reporting periods on a consistent basis by excluding items that the company does not believe are indicative of its core operating performance.

These adjusted measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. The company's definition of these adjusted measures may differ from similarly titled measures used by others.

Because adjusted financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety.

Guidance on the company's 2019 diluted earnings per share and effective tax rate has been provided only on a non-GAAP basis. This is due to the inherent difficulty of forecasting the timing or amount of items that would be included in the most directly comparable forward-looking GAAP financial measures. Because reconciliation is not available without unreasonable effort, it is not included in this release.


Statements in this document that are not strictly historical, including statements regarding future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting Mallinckrodt's businesses, plans for the Specialty Generics business including the suspension of the previously announced plans to spin off that business, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.

There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Mallinckrodt operates; the commercial success of Mallinckrodt's products; Mallinckrodt's ability to realize anticipated growth, synergies and cost savings from acquisitions; conditions that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets for possible impairment; changes in laws and regulations; Mallinckrodt'sability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings; Mallinckrodt's and Mallinckrodt's licensers' ability to successfully develop or commercialize new products; Mallinckrodt's and Mallinckrodt's licensers' ability to protect intellectual property rights; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; the reimbursement practices of a small number of public or private insurers; pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; limited clinical trial data for Acthar Gel; complex reporting and payment obligations under healthcare rebate programs; Mallinckrodt's ability to navigate price fluctuations; future changes to U.S. and foreign tax laws; Mallinckrodt's ability to achieve expected benefits from restructuring activities; complex manufacturing processes; competition; product liability losses and other litigation liability; ongoing governmental investigations; material health, safety and environmental liabilities; retention of key personnel; conducting business internationally; the effectiveness of information technology infrastructure and cybersecurity and data leakage risks; Mallinckrodt's substantial indebtedness and its ability to generate sufficient cash to reduce its indebtedness and any future actions taken with respect to the Specialty Generics business.

These and other factors are identified and described in more detail in the 'Risk Factors' section of Mallinckrodt's Annual Report on Form 10-K for the fiscal year ended December 28, 2018. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.


Daniel J. Speciale

Tel: 314-654-3638


[Editorial queries for this story should be sent to]

((Distributed via M2 Communications -
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ENP Newswire
Date:Aug 7, 2019
Previous Article:Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure...
Next Article:Zynerba Pharmaceuticals Announces Publication of Zygel 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |